)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
FluoGuide
FluoGuide (FLOU) investor relations material
FluoGuide Investing in Life Science 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investing in Life Science 2026 summary22 Sep, 2026
Market opportunity and technology
Cancer recurrence after surgery is a major problem, addressed by a drug that lights up cancer during surgery.
The solution targets uPAR, an enzyme highly expressed in aggressive cancers, enabling visualization.
Market potential is significant, with 45 million cancer procedures projected in 2030.
Clinical validation and regulatory progress
Clinical trials have been conducted, and FDA granted Fast Track designation for high-grade glioma.
Partnerships with major med tech companies are in place to facilitate market penetration.
The drug is administered pre-surgery, binds to cancer, and enables real-time visualization during operations.
Focus areas and clinical endpoints
Focus is on brain tumors (especially high-grade glioma) and head and neck cancers.
The technology helps surgeons distinguish cancer from normal tissue, reducing unnecessary removal.
Primary clinical endpoint is removal of contrast-enhancing tumor; secondary endpoint is removal of infiltrative cancer.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from FluoGuide
- FG001 cleared safety review, supporting Phase II planning and broader cancer development.FLOU
Investor Call - FDA Fast Track and pivotal U.S. trial site activation drive clinical and financial progress.FLOUQ2 2026
- FDA Fast Track and IND approval drive clinical progress and cash runway through Q1 2027.FLOUQ1 2026
- Regulatory progress, capital raise, and positive clinical data support future growth.FLOUQ4 2025
- FG001 enables precise cancer surgery, backed by strong data, partnerships, and secured funding.FLOUSEB Nordic Seminar presentation
- Regulatory clarity, strong financing, and clinical progress position FG001 for approval.FLOUQ3 2025
- Innovative imaging agent lights up cancer for surgeons, targeting broad markets with strong FDA support.FLOUInvesting in Life Science 2025
- Clinical milestones and strategic partnerships advance FG001, despite ongoing net losses.FLOUQ2 2025
- FG001 advances toward approval with positive clinical data and improved financials.FLOUQ3 2024
Next FluoGuide earnings date
Q3 202626 Nov, 2026
FluoGuide
Next FluoGuide earnings date
Q3 202626 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
FluoGuide is a Danish clinical-stage biotech company specializing in the development of products used to improve cancer surgery. FluoGuide's main product, FG001, is designed to illuminate brain cancer cells during surgery, enabling surgeons to distinguish them more easily from healthy tissue. FG001 is designed to bind specifically to cancer cells, making them visible under a special light during surgery. This aims to reduce the risk of leaving cancerous tissue behind, potentially increasing the success rate of surgeries. The company is also actively researching whether its fluorescent technology can be employed to potentially improve surgery outcomes for a variety of different cancers. FluoGuide is headquartered in Copenhagen, and its shares are listed on Nasdaq Stockholm.